

WATSON PHARMACEUTICALS INC  
Form 8-K  
January 04, 2007

## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

December 29, 2006

Date of Report (Date of earliest event reported)

## WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other Jurisdiction  
of Incorporation)

**0-20045**

(Commission File Number)

**95-3872914**

(IRS Employer  
Identification Number)

**311 Bonnie Circle  
Corona, California**

(Address of principal executive  
offices)

**92880**

(Zip Code)

**(951) 493-5300**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 8-K

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02** Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On December 29, 2006, James A. Nash resigned from his position as Executive Vice President, Technical Operations, effective January 12, 2007, in order to pursue another employment opportunity.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 4, 2007.

WATSON PHARMACEUTICALS, INC.

By: /s/ David A. Buchen  
David A. Buchen  
Senior Vice President, General Counsel & Secretary

---